The Effects of Low-Dose Aspirin and Selective Inhibitors of Thromboxane-Synthase on Eicosanoid Production in Man

  • Carlo Patrono
  • Paola Filabozzi
  • Paola Patrignani
Part of the NATO ASI Series book series (NSSA, volume 95)


The appreciation that two cyclooxygenase products, i.e. prostacyclin (PGI2) and thromboxane (TX) A2 have potent and contrasting effects on platelet function and vascular tone (see ref. 1 for a review) has prompted attempts to develop selective pharmacologic tools affecting their production with the aim of under standing their pathophysiologic role and possibly treating human disease states. Two different approaches have been followed; 1) differential inhibition, of platelet vs vascular cyclooxygenase by low-dose aspirin 2,3,4 and 2) selective inhibition of TX-sypthase by a variety of imidazole derivatives, such as dazoxiben5,6 , UK- 38,4857, CGS 130808 and OKY-0469. The former has a clear advantage in achieving a profound and long-lasting suppression of platelet TXA2 production with a high safety margin and low cost. The latter approach has theoretically two distinct advantages over low-dose aspirin, i.e. it can result in enhanced PGI2 production by virtue of platelet-derived prostaglandin (PG) endoperoxides, and it can be expected to inhibit TXA2 production in all TXA2-producing cells.


Healthy sUbjects2 Thromboxane Synthetase Human Disease State Biosynthesis Eicosanoid PGI2 Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P.W. Majerus, Arachidonate metabolism in vascular disorders, J.Clin. Invest, 72: 1521 (1983).CrossRefGoogle Scholar
  2. 2.
    P. Patrignani, P. Filabozzi and C. Patrono, Selective cumulative inhibition of platelt thromboxane production by low-dose aspirin in healthy subjects, J.Clin. Invest. 69: 1366 (1982).CrossRefGoogle Scholar
  3. 3.
    G.A. FitzGerald, J.A. Oates, J. Hawiger, R.L. Maas, L.J. Roberts II, J.A. Lawson and A.R. Brash, Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man, J. Clin. Invest. 71: 676 (1983).PubMedCrossRefGoogle Scholar
  4. 4.
    B.B. Weksler, S.B. Pett, D. Alonso, R.C. Richter, P. Stelzer, V. Subramanian, K. Tack-Goldman, and W.A. Gay, Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients, N. Engl. J. Med. 308: 800 (1983).PubMedCrossRefGoogle Scholar
  5. 5.
    G.A. FitzGerald, A.R. Brash, J.A. Oates and A.K. Pedersen, Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man, J. Clin. Invest. 71: 1336 (1983).CrossRefGoogle Scholar
  6. 6.
    P. Patrignani, P. Filabozzi, F. Catella, F. Pugliese and C. Patrono, Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism, J. Pharmacol. Exp. Ther. 228: 472 (1984).PubMedGoogle Scholar
  7. 7.
    S. Fisher, M. Struppler, B. BÖhlig, C. Bernutz, W. Wober, and P.C, Weber, The influence of selective thromboxane synthetase inhibition with a novel imidazole-derivative, UK-38,485, on prostanoid formation in man, Circulation 68: 821 (1983).CrossRefGoogle Scholar
  8. 8.
    G.A. FitzGerald and J.A. Oates, Selective and nonselective inhibition of thromboxane formation, Clin. Pharmacol. Ther. 35: 633 (1984).CrossRefGoogle Scholar
  9. 9.
    P. Patrignani, F. Catella, P. Filabozzi•, F. Pugliese, A. Pie, rucci,_B.M..Simonetti, L. Forni, M. Segni and C. Patrono, Differential effects of OKY-046, a selective thromboxane synthase inhibitor., on platelet and renal prostaglandin endoperoxide metabolism, Clin. Res. 32: 246A, (abstract) (1984)Google Scholar
  10. 10.
    G.A. FitzGerald, A.K. Pedersen and C. Patrono, Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease, Circulation 67: 1174 (1983).PubMedCrossRefGoogle Scholar
  11. 11.
    C. Patrono, G. Ciabattoni, B.M. Peskar, F. Pugliese, and B.A. Peskar, Is plasma 6-keto-PGF1α a reliable index of circulating Prostacyclin ? Clin. Res. 29: 276A (abstract) (1981).Google Scholar
  12. 12.
    G. Ciabattoni, F. Pugliese, G.A. Cinotti, G. Stirati, R.Ronci, G. Castrucci, A. Pierucci and C. Patrono, Characterization of furosemide induced activation of the renal Prostaglandin system, Eur. J. Pharmacol. 60: 181 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    C. Patrono, F. Pugliese, G. Ciabattoni, P. Patrignani, A. Maseri, S. Chierchia, G.A. Cinotti, B.M. Simonetta, Pierucci A. and B.A. Peskar, Evidence for a direct stimulatory effect of prostacyclin on renin release in man, J. Clin. Invest. 69: 231 (1982).PubMedCrossRefGoogle Scholar
  14. 14.
    G. Ciabattoni, G.A. Cinotti, A. Pierucci, B.M. Simonetti, M. Manzi, F. Pugliese, P. Barsotti, G. Pecci, F. Taggi and C. Patrono, Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin, N. Engl. J. Med. 310: 279 (1984)PubMedCrossRefGoogle Scholar
  15. 15.
    C. Patrono, G. Ciabattoni, P. Patrignani, P. Filabozzi, E. Pinca, M.A. Satta, D. Van Dorne, G.A. Cinotti, F, Pugliese, A. Pie-rucci and B.M. Simonetti, Evidence for a renal origin of urinary thromboxane B2 in health and disease, Adv. Prostaglandin, Thromboxane and Leukotriene Res. 11: 493 (1983).Google Scholar
  16. 16.
    C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, A. De Salvo, M.A. Satta and B.A. Peskar, Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects, Thromb. Res. 17: 317 (1980).Google Scholar
  17. 17.
    F.E. Preston, S. Whipps, C.A. Jackson, A.J. French, P.J. Wyld and C. J. Stoddard, Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin, N. Engl. J. Med. 304: 76 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    P. Alessandrini, P. Avogaro, G. Bittolo Bon, P. Patrignani and C. Patrono, Physiologic variables affecting thromboxane B2 production in human whole blood, Thromb. Res, in press.Google Scholar
  19. 19.
    A.K. Pedersen, M.L. Watson and G.A. FitzGerald, Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1α, Thromb.Res. 33: 99 (1984).PubMedCrossRefGoogle Scholar
  20. 20.
    G.J. Roth, N.S..Stanford,and P.W. Majerus, Acetylation of prostaglandin synthetase by aspirin, Prot. Acad. Sci. USA72: 3073 (1975).CrossRefGoogle Scholar
  21. 21.
    F.J. Van der Ouderaa, M. Buytenhek, D.H. Nugteren and.D.A. Van Dorp, Acetylation of Prostaglandin endoperoxide synthetase with acetylsalicylic acid, Eur. J. Biochem. 109: 1 (1980).CrossRefGoogle Scholar
  22. 22.
    J.W. Burch, N. Stanford and P.W. Majerus, Inhibition of platelet prostaglandin synthetase by oral aspirin, J. Clin. Invest. 61: 314 (1978).CrossRefGoogle Scholar
  23. 23.
    C.Patrono, G. Ciabattoni, P, Patrignani, F. Pugliese, P. Ftlabozzi, F..Catella, G..Davì and L. Forni, Clinical Pharmacology of platelet cyclooxygenase.inhibition, Circulation in press.Google Scholar
  24. 24.
    A.K. Pedersen and G.A. FitzGerald, Dose related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase in man, N. Engl. J. Med., in press.Google Scholar
  25. 25.
    G. Di Minno, M.J. Silver, and S. Murphy, Monitoring the entry of new platelets into the circulation after ingestion of aspirin, Blood 61: 1081 (1983).PubMedGoogle Scholar
  26. 26.
    H.R. Harter, J.W. Burch, P.W. Majerus, N. Stanford, J.A. Delmez, C.B. Anderson and C.A Weerts, Prevention of thrombosis in patients on hemodialysis by low-dose aspirin, N. Engl. J. Med. 301: 577 (1979).PubMedCrossRefGoogle Scholar
  27. 27.
    H.D Lewis, J.W. Davis, D.G. Archibald, W.E. Steinke, T.C. Smitherman, J.E. Doherty, H.W. Schnaper, M.M. LeWinter, E. Linares, J.M. Pouget, S.C. Sabharwal, E. Chester and H. DeMots, Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study, N. Engl. J. Med. 309: 396 (1983).PubMedCrossRefGoogle Scholar
  28. 28.
    R.L. Lorenz, M. Weber, J. Kotzur, K. Theisen, C.V. Schacky, W. Meister, B. Reichardt and P.C. Weber, Improved aortocoronary bypass patency by-low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation, Lancet I: 1261 (1984).Google Scholar
  29. 29.
    H.D. Lewis Jr. and J.W. Davis, Aspirin and the risk of myocardial infarction, N. Engl. J. Med. 310: 122 (1984).CrossRefGoogle Scholar
  30. 30.
    P.M. Steele, J.H. Chesebro and V. Fuster, The natural history of arterial balloon angioplasty in pigs and intervention with platelet-inhibitor therapy: implications for clinical trials, Clin. Res. 32: 209A (abstract) (1984).Google Scholar
  31. 31.
    G.A. FitzGerald, B. Smith, A.K. Pedersen and A.R. Brash, Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation, N. Engl. J. Med. 310: 1065 (1984).PubMedCrossRefGoogle Scholar
  32. 32.
    R. De Caterina, D. Giannessi, W. Bernini, P. Gazzetti, C. Michelassi, A. L’Abbate, L. Donato, P. Patrignani, P. Filabozzi and C. Patrono, Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function, Am. J. Cardiol. in press.Google Scholar
  33. 33.
    B.B. Weksler, K. Tack-Goldman, V. Subramanian and W.A. Gay jr., Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis, Circulation, in press.Google Scholar
  34. 34.
    G. Boysen, A. Hasager Boss, N. Odum.and J.S. Olsen, Prolongation of bleeding time and inhibition of platelet aggregation by low-dose acetylsalicylic acid in patients with cerebro-vascular disease, Stroke 15: 241 (1984)Google Scholar
  35. 35.
    B.B. Weksler, J.L. Kent, D. Rudolph, P. Scherer and D.E. Levy, Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke, in press.Google Scholar
  36. 36.
    L. Roy, H.R. Knapp, R.M. Robertson and G.A. FitzGerald, Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man, Circulation, in press.Google Scholar
  37. 37.
    G.A. FitzGerald, A.R. Brash, P. Falardeau and J.A. Oates, Estimated rate of prostacyclin secretion into the circulation of normal man, J. Clin. Invest. 68: 1272 (1981).PubMedCrossRefGoogle Scholar
  38. 38.
    S. Chierchia, C. Patrono, F. Crea, G. Ciabattoni, R. De Caterina, G.A. Cinotti, A. Distante and A. Maseri, Effects ofintravenous prostacyclin in variant angina, Circulation 65: 470 (1982).PubMedCrossRefGoogle Scholar
  39. 39.
    V. Bertelè, A. Falanga,.M. Tomasiak, E. Dejana, C. Cerletti and G. de Gaetano, Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the “aspirin dilemma”, Science 220: 517 (1983).PubMedCrossRefGoogle Scholar
  40. 40.
    M.A. Orchard, I.A. Blair, C.T. Dollery and P.J. Lewis, Blood can synthesize prostacyclin, Lancet II: 565 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Carlo Patrono
    • 1
  • Paola Filabozzi
    • 1
  • Paola Patrignani
    • 1
  1. 1.Department of Pharmacology and Centro di Studio per la Fisiopatologia dello Shock C.N.R.Catholic University School of MedicineRomeItaly

Personalised recommendations